Phospholipogenic Pharmaceuticals Are Associated with a Higher Incidence of Histological Findings than Nonphospholipogenic Pharmaceuticals in Preclinical Toxicology Studies by Barone, Linda R. et al.
Hindawi Publishing Corporation
Journal of Toxicology




a Higher Incidenceof Histological Findingsthan
NonphospholipogenicPharmaceuticals in Preclinical
ToxicologyStudies
Linda R. Barone,1 Scott Boyer,2 James R. Damewood, Jr,3 James Fikes,4 andPaulJ. Ciaccio4
1Biologics Research, Janssen Research and Development, LLC, 145 King of Prussia Road, Radnor, PA 19087, USA
2Safety Assessment, AstraZeneca Pharmaceuticals, Pepparedsleden 1, 431 83 M¨ olndal, Sweden
3Haskell Global Centers for Health and Environmental Sciences, DuPont Central Research and Development, Newark,
DE 19711, USA
4Safety Assessment, AstraZeneca Pharmaceuticals, 35 Gatehouse Drive, Waltham, MA 02451, USA
Correspondence should be addressed to Paul J. Ciaccio, paul.ciaccio@astrazeneca.com
Received 15 March 2012; Accepted 10 April 2012
A c a d e m i cE d i t o r :J .J .S t e g e m a n
Copyright © 2012 Linda R. Barone et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
While phospholipidosis is thought to be an adaptive response to chemical challenge, many phospholipogenic compounds
are known to display adverse eﬀects in preclinical species and humans. To investigate the link between phospholipogenic
administration and incidence of preclinical histological signals, an internal AstraZeneca in vivo toxicology report database
was searched to identify phospholipogenic and nonphospholipogenic compounds. The datasets assembled comprised 46
phospholipogenic and 62 nonphospholipogenic compounds. The phospholipogenic potential of these compounds was conﬁrmed
by a pathologist’s interpretation and was supported by well-validated in silico and in vitro models. The phospholipogenic dataset
contained 37 bases, 4 neutral compounds, 3 zwitterions, and 1 acid, whereas the nonphospholipogenic dataset contained 9 bases,
34 neutrals, 1 zwitterion, and 18 acids. Histologic ﬁndings were tracked for adrenal gland; bone marrow; kidney; liver; lung;
lymph node; spleen; thymus; and reproductive organs. On average, plasma exposures were higher in animals dosed with the
nonphospholipogenics. Phospholipogenics yielded proportionally more histologic changes (exclusive of phospholipidosis itself)
in all organs. Statistically signiﬁcant higher frequencies of liver necrosis, alveolitis/pneumonitis, as well as lymphocytolysis in the
thymus, lymph nodes, and spleen occurred in response to phospholipogenics compared to that for nonphospholipogenics.
1.Introduction
Drug-induced phospholipidosis (PLD) is a lipid storage
disordercharacterizedbytheintralysosomalaccumulationof
polar lipids, membranous lamellar inclusions, and drug. The
cytological features of PLD mimic inherited lipidoses [1].
Common primary tissue targets are alveolar macrophages,
hepatic Kupﬀer cells, bile duct epithelia, and peripheral
blood mononuclear cells, although numerous other cellular
targets have been reported. Many marketed and experimen-
tal drugs have been reported to cause PLD preclinically
[2]. Most have basic and hydrophobic physicochemical
properties (amphiphilic cations) that enable binding with
phospholipids, crossing of biological membranes, and lyso-
motropism (partitioning of drug into lysosomes once it is
protonated at acidic intralysosomal pH) [3]. Lysomotropic
properties and drug accumulation potential are underscored
by studies employing lysosomal modulators which have
a demonstrated ability to abolish the pH gradient from
cytoplasmtolysosome,precludeaccumulationofdruginthe
lysosome (depot eﬀect), and/or rescue cells in vitro [4–6].
There is a consensus view that PLD itself is largely an
adaptive rather than an adverse response to xenobiotics as a
number of ex vivo studies have failed to consistently reveal
speciﬁc functional detriment in responding phospholipi-
dotic tissues [2, 7–9]. Yet there is suggestive evidence that2 Journal of Toxicology
Table 1:Nominaldosesandexposuresfromboththenonphospholipogeniccompound(NP)andphospholipogeniccompound(P)datasets.
Averages and standard deviations (in parentheses) shown. Data from mid-doses are not shown. Average phospholipogenic plasma exposures
were lower for all species across all doses than exposures from the negative dataset, but diﬀerences were not statistically signiﬁcant.
Species Low dose (µmol/kg) Low Cmax (µM) Low AUC (µM·hr) High dose (µmol/kg) High Cmax (µM) High AUC (µM·hr)
Dog (NP) 89 (124) 52 (71) 297 (429) 936 (1266) 253 (334) 2561 (4457)
Dog (P) 47 (67) 9 (13) 102 (177) 467 (614) 27 (20) 335 (345)
Mouse (NP) 323 (182) 15 (16) 52 (60) 2018 (1437) 56 (71) 322 (519)
Mouse (P) 117 (83) 6 (5) 65 (80) 958 (635) 62 (108) 320 (446)
Rat (NP) 162 (356) 25 (51) 224 (671) 1351 (2659) 204 (390) 1377 (2607)
Rat (P) 235 (384) 9 (21) 117 (324) 737 (802) 26 (32) 372 (485)
phospholipogenic compounds are associated with concur-
rent toxicities preclinically and clinically. These toxicities
include liver necrosis (amiodarone), motor neuropathies
(imipramine, amitriptyline), proximal tubule kidney injury
(gentamicin), pulmonary alveolitis that can progresses to
ﬁbrosis (amiodarone), pneumonitis (ﬂuoxetine), peripheral
neuropathies (suramin, amiodarone, chloroquine, perhexi-
line), and corneal opacity (chloroquine, amiodarone) [10–
15]. Despite this potential association, to date, there have
been no comprehensive published reviews of pharmaceutical
industrydatathatenumeratetheserisksorthatprobethesta-
tistical connection between phospholipogenic compounds
and concurrent toxicities. Understanding whether such a
connection exists would help deﬁne the relative importance
of thorough pathological characterization of phospholipido-
sisandconcurrenttoxicitiesinearlydrugdiscoveryandassist
in reducing attrition in drug development.
To investigate the link between phospholipogenic com-
pound administration and the incidence of preclinical histo-
logical signals, phospholipogenic and nonphospholipogenic
compounds were identiﬁed in an internal AstraZeneca in
vivo toxicology report database and their histological results
annotated. We herein report on a robust, unbiased analysis
revealing that in vivo phospholipogenic compounds are
statistically more likely to demonstrate non-PLD histologic
changes in all organs investigated. This observation is even
more compelling when one considers that, in these studies,
the nominal dose (or exposures) for nonphospholipogenic
compounds typically exceeded that for phospholipogenic
compounds.
2. Methods
2.1. Compound Identiﬁcation. An internal AstraZeneca
database containing repeat-dose in vivo toxicology reports
was searched to identify phospholipogenic compounds
using the common PLD indicator terms phospholipidosis,
histiocytosis, foamy macrophages, lamellar lysosomes, and
myeloid bodies. To identify reports on nonphospholipogenic
compounds, the database was searched for the absence
of these PLD indicator terms. Species, study duration,
histological ﬁndings, nominal doses, and plasma exposures
were the key data extracted. We focused on nine responding
organs: adrenal gland; bone marrow; kidney; liver; lung;
lymph node; reproductive organs;spleen; thymus. (While we
have observed nervous and muscle tissue phospholipidosis
in our studies, reports were not archived in time, or search
terms were inadequate for the purpose of performing an
unbiased analysis.)
Reports were individually read to verify the presence or
absence of indicator terms, and both PLD and all non-PLD
histologic ﬁndings were recorded and annotated. Although
PLD often presents as vacuolation by light microscopy, due
to its common occurrence, by itself, this ﬁnding was not
considered suﬃcient for PLD classiﬁcation. One or more
of the following was considered an additional conﬁrming
measure for membership in the phospholipogenic dataset:
ap o s i t i v er e s u l ti na nin vitro PLD assay [16], a positive
prediction from our in-house in silico PLD model, a
pathologist interpretation/description of PLD in the report
(PLD had to be considered by the pathologist a familiar
and salient ﬁnding and not that of background), or an
electron microscopic ﬁnding of PLD, the latter being the
gold standard for detecting lysosomal phospholipid-laden
myeloid inclusions indicative of PLD. One or more of the
following was considered an additional conﬁrming measure
of a compound having a nonphospholipogenic status: a
negative result in an in vitro PLD assay or a negative result
in our in silico PLD predictive model.
2.2. Pharmacokinetic Properties. Nominal dose (µmol/kg),
AUCµm·hr and Cmax (µM) plasma exposure data for the two
compound classes were extracted from the study reports if
available (Table 1). The majority of the study reports had
threedosegroups.Ifastudyhadfourdosegroups,thesecond
lowest dose was designated as the low dose. AUC exposure
information for at least two doses was available for 77%
of the phospholipogenic reports and 86% of the negative’s
reports; Cmax exposure information for at least 2 doses was
available for 73% of the phospholipogenic compounds and
79% of the nonphospholipogenic compounds. Exposures
were not adjusted for plasma protein binding as complete
measurements were not available for a majority of the
studies.
2.3. Statistical Analysis. Statistically signiﬁcant diﬀerences
between the two datasets for organ histological ﬁndings
were assessed using Chi Square analysis at a 95% conﬁdence
level. Statistically signiﬁcant diﬀerences are indicated by Chi
Square values greater than 3.84 in Table 2.Journal of Toxicology 3
Table 2: Incidence of nonphospholipidosis histological ﬁndings (HFs) for liver, kidney, lung, adrenals, and lymphoid tissues for 46
phospholipogenics and 62 nonphospholpogenics. Results are presented as the total number of compounds exhibiting (or not exhibiting—
“No ﬁndings”) the given histological ﬁnding and the percentage of the total number of compounds in that category. ChiSquare values of
≥3.84 conferred statistical signiﬁcance at P<0.05∗.Statistical signiﬁcance was achieved for select histological ﬁndings inliver, lung, thymus,
lymph node, and spleen but not kidney and adrenal glands. HF: histological ﬁndings.
Phospholipogenics Nonphospholipogenics
Chi-Sq∗
Total number Percent of total
compounds Total number Percent of total
compounds
Liver
N e c r o s i s / d e g e n e r a t i o n 2 24 81 32 1 8 . 7 ∗
H y p e r t r o p h y 1 22 61 11 8 1.1
Reduced glycogen
vacuolation 81 75 8 2.2
No ﬁndings 14 30 32 52 4.8∗
Kidney
Necrosis/degeneration 8 17 6 10 1.4
Nephropathy 5 11 5 8 0.25
No ﬁndings 27 59 40 65 0.28
Lung
Pneumonitis 5 11 0 0 7.1∗
O e d e m a 3712 1.8
Alveolitis 3 7 0 0 4.2∗
No ﬁndings 34 74 61 98 14.9∗
Adrenal gland
H y p e r t o p h y 51 15 8 0.25
N e c r o s i s 4923 1.5
No ﬁndings 30 65 46 74 1.1
Thymus
Lymphocytolysis,
lymphoid depletion 16 35 6 10 10.3∗
Atrophy/involution 13 28 16 26 0.08
No ﬁndings 22 48 43 69 5.1
Lymph node
Lymphocytolysis,
lymphoid depletion 12 26 1 2 14.9∗
A t r o p h y 2458 0.6
No ﬁndings 28 61 52 84 7.3∗
Spleen
Lymphocytolysis,
lymphoid depletion 81 70 0 11.7∗
Altered hematopoiesis 4 9 6 10 0.01
A t r o p h y 4935 0.65
A p o p t o s i s 3700 4.2∗
No ﬁndings 30 65 52 84 5.0∗
3. Results
3.1. Source Data for Phospholipogenic and Nonphopholi-
pogenic Compounds. In vivo data extracted from an internal
in vivo toxicology report archive resulted in compilation
of forty-six phospholipogenic compounds and sixty-two
nonphospholipogenic compounds. To obtain the forty-six
phospholipogenic compound set, ﬁfty-three compounds
initially identiﬁed as phospholipogenics based on verbal
descriptors in the study reports were tested in our in vitro
PLD assay [16], found to be positive, and selected for further
analysis. The majority of these compounds exhibited in vitro
EC50 values less than 50µM( m e a n4 4 µM, sd 66; ranging
from2.4to273µM).Forcomparison,thephospholipogenics
amiodarone, chloroquine, and citalopram yield 4.8, 12,
and 38µME C 50 values in this assay, demonstrating that4 Journal of Toxicology
many positives selected for analysis were intrinsically weaker
in their phospholipidosis inducing potential than these
standard reference drugs.
3.2. Physiochemical Properties Analyses. The 107 compounds
in the phospholipogenic and nonphospholipogenic datasets
were structurally diverse. Clustering based on 2-dimensional
molecular ﬁngerprints resulted in seventy-ﬁve sets of com-
pounds,withthelargestclustercontainingeightcompounds.
Physical and computed molecular properties also revealed
this diversity, with molecular weights (MW) ranging from
139 to 696 (mean 434, sd 115), polar surface area (PSA)
between 20.5 and 194.9 (mean 85.9, sd 33.4), and ClogP
between −2.53 and 8.95 (mean 3.0, sd 2.0). The number of
hydrogen bond donors ranged from 0 to 4 (mean 1.7, sd 1.2)
andh ydrogenbondacceptorsfrom2to14(mean6.9,sd2.4).
At pH 7, the phospholipogenic compounds were predicted
to contain 37 bases, 4 neutrals, 3 zwitterions, and 1 acid,
while the nonphospholipogenic compounds contain 9 bases,
34neutrals,1zwitterion,and18acids.Thisisconsistentwith
the generalization that many phospholipogenic compounds
are amphiphilic cations. The MW for the phospholipogenic
compounds ranged between 256 and 645 (mean 476, sd
85) and 139 and 695 (mean 404, sd 124) for the negative
compounds. ClogP for the phospholipogenic compounds
range between 0.67 and 8.95 (mean 3.8, sd 1.6) and for
the negative compounds between −2.53 and 7.46 (mean
2.4, sd 2.0). PSA for the phospholipogenics ranged between
30.6 and 138.1 (mean 76.4, sd 25), while, for the nonphos-
pholipogenic compounds it ranges between 20.5 and 194.9
(mean 92.8, sd 37.2). The number of hydrogen bond donors
ranges between 0 and 4 (mean 1.5, sd 1.1) and the number
of hydrogen bond acceptors between 3 and 12 (mean 6.9,
sd 1.8) for the phospholipogenic compounds and between
0 and 4 (mean 1.8, sd 1.2) and 2 and 14 (mean 6.9, sd
2.7), respectively, for the negatives. Aside from the obvious
diﬀerence in the ionization characteristics of the two sets,
these simple physical chemical parameters alone do not
appear to eﬀectively distinguish between phospholipogenic
and nonphospholipogenic compounds.
3.3. Species, Study Durations, and Plasma Exposures. Mouse,
rat, and dog are the three species represented in the
compound datasets. Study durations ranged from ﬁve days
to two years, with the majority of repeat dose studies having
been conducted for 1 to 4 weeks duration. Figure 1 shows
the percentage of study reports by species. Figure 2 shows the
percentage of study reports by study duration. There were on
average 4.8 (4.6 sd) and 3.2 (2.3 sd) reports per compound
in the phospholipogenic and nonphospholipogenic datasets,
respectively. Where there were multiple study reports for a
compound tested in the same species, reports were counted
as a single “report” to minimize weighting bias. There
were some notable diﬀerences in the distribution of study
species and duration for both compound classes. There were
29% (of the total) (or 1.6-fold) more rat study “reports”





















Figure 1: Percentage of study reports by species for both
phospholipogenic and nonphospholipogenic datasets. Where there
were multiple study reports for a compound tested in the same
species, reports were counted as a single “report” to minimize
weighting bias. There were 29% (of the total) (or 1.6-fold) more rat
study “reports” available in the phospholipogenic dataset than the
negativesdataset,whereastherewere28%(ofthetotal)(or2.8-fold)
more dog study “reports” available in the negative dataset than the
phospholipogenic dataset. Phospholipidosis potential (descriptors
and pathologists interpretation) identiﬁed in study reports for all
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Figure 2: Percentage of study reports for both nonphospholi-
pogenic and phospholipogenic datasets by study duration. Where
there were multiple study reports for a compound tested in the
same species, reports were counted as a single “report” to minimize
weighting bias. There were 15% (of the total) (or 1.7-fold) more
2-week “reports” available for the phospholpogenic dataset than
for the negatives; there were 26% (of total) (or 1.7-fold) more
4-week “reports” available for the negative dataset than for the
phospholpogenics. The larger ﬁgure reﬂects data pooled from the
threespecies.Theinset showsthebreakdownoftwo-weekandfour-

































Number of organs with PLD
Figure 3: Number of phospholipogenic compounds by incidence
of organ phospholipidosis responses. The values above the bars
represent proportions of the compounds yielding a phospholipi-
dosis response descriptor (i.e., “phospholipidosis,” “histiocytosis,”
“foamy macrophages,” “lamellar lysosomes,” and “myeloid bodies”
and where phospholipidosis potential was conﬁrmed by in silico
or in vitro testing). Approximately half of the compounds caused
multiorgan PLD (i.e., ≥3 organs) phospholipogenics. The data
represent that pooled from three species and all study durations.
dataset, whereas there were 28% (of the total) (or 2.8-
fold) more dog study “reports” available in the negative
dataset than the phospholipogenic dataset. The percentage
of mouse reports was equivalent for both compound classes.
The two-week and four-week groupings had the greatest
variation in study duration distribution. There were 15% (of
the total) (or 1.7-fold) more 2-week “reports” available for
the phospholpogenic dataset than for the negatives; there
were 26% (of total) (or 1.7-fold) more “reports” available
for the negative dataset than for the phospholpogenics.
Except for mouse where AUCµm·hr and Cmax (µM) exposure
data were similar between datasets at high nominal doses,
nominal dose (µmol/kg), AUCµm·hr,a n dC max (µM) values
for the negative compounds were on average higher for
the other two species (Table 1). Cmax exposures from the
nonphospholipogenic bin on average well exceeded 10µM.
3.3.1. Phospholipogenic Compound Incidence of Organ PLD
versus Non-PLD Findings. Compound treatments yielding
three or more organ PLD responses were deemed multi-
organ phospholipogenic compounds. Approximately 50%
of phospholipogenic compounds caused multiorgan PLD
(Figure 3). Multiorgan PLD was more likely to occur when
predicted percent free compound (free of protein binding)
was greater than ∼10%, whereas PLD more often occurred
in only one to two organs when the predicted percent free
was less than 10%. PLD incidence by organ is illustrated in
Figure 4. Lung, lymph node, and spleen presented with the
highest incidence, bone marrow, and thymus the lowest. The
liver PLD incidence was approximately 35%. In contrast, the
rank order of non-PLD histologic ﬁndings incidence for this
dataset diﬀered from that of organ PLD ranking (Figure 5).
Liver and thymus exhibited the highest incidences of non-
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Figure 4: Percent phospholipogenics giving histological ﬁndings
consistent with phospholipidosis, by organ. In response to phos-
pholipogenic administration, lung and lymph node presented
with the greatest number of histological ﬁndings that matched
phospholipidosis descriptors whereas bone marrow and thymus
presented with the least. The data represent that pooled from three
species and all study durations.
3.4. Incidence of Organ Non-PLD Histologic Findings, Com-
paring Phospholipogenic, and Nonphospholipogenic Datasets.
To ascertain which dataset was associated with more histo-
logic ﬁndings, frequencies of non-PLD histologic ﬁndings
were compared. Phospholipogenic compounds consistently
exhibited more non-PLD histologic changes for all organs
(Figure 6), and among these the liver exhibited the high-
est percentage of histologic ﬁndings for both datasets.
Compared to nonphospholipogenic compounds, phospho-
lipogenic compounds yielded a statistically signiﬁcant higher
percentage of liver necrosis ﬁndings (Table 2). For those
phospholipogenic compounds in this subset where exposure
data were available (i.e., 11 of 22 compounds that caused
necrosis), top plasma exposures did not on average exceed
those phospholipogenics that did not cause necrosis (data
not shown). A statistically signiﬁcant, higher frequency of
lymphocytolysis/lymphoid depletion in lymphoid organs
increased apoptosis in spleen, and alveolitis/pneumonitis
in lung were observed with this subset of compounds. No
diﬀerences were apparent for adrenals or kidney. Finally, sta-
tistically signiﬁcant higher levels of “no histologic ﬁndings”
in the liver, lung, thymus, lymph nodes, and spleen were
reported for the nonphospholipogenic compounds.
4. Discussion and Conclusions
The purpose of this study was to test whether pharmaceuti-
cally relevant phospholipogenic compounds were associated
with a higher frequency of histologic changes in repeat dose
in vivo preclinical toxicology studies than that for non-
phospholipogenic compounds. For the comparison, forty-
six phospholipogenic compounds were identiﬁed; sixty-
two negative compounds were identiﬁed. Results of the
analysis may be summarized as follows. Phospholipogenic
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Figure 5: Percent phospholipogenics with nonphospholipogenic
histological ﬁndings by organ. The data represent that pooled from
three species and all study durations.
non-PLD histologic changes in general in all organs exam-
ined and for select histological ﬁndings in liver, lung,
thymus, lymph node, and spleen but not for kidney and
adrenal glands. Nonphospholipogenic compounds exhibited
a higher incidence of “no ﬁndings” for several organs. Phos-
pholipogenic compounds exhibited statistically signiﬁcant
increases in lung alveolitis/pneumonitis and in true toxicities
relating to liver necrosis. Not surprisingly, phospholipogenic
compounds demonstrating “no liver ﬁndings” tended to
exhibit fewer histological ﬁndings across the 9 organs overall
(data not shown). Increased incidences of lymphocytoly-
sis and/or lymphoid depletion in three lymphoid tissues
(thymus, lymph nodes, and spleen) were also observed
in the phospholipogenic dataset. Lymphocytolysis/lymphoid
depletion is often attributed to high-dose-mediated stress
responses; but they may in some instances represent a true
toxicological response. Without other hematologic correlates
it is not possible to shed light on this matter, and for this
reason labeled these results conservatively simply as excess
histological ﬁndings. Finally, it also appears from the study
duration analysis that two-week study designs and the rat
model are typically suﬃcient to capture phospholipidotic
signals in vivo. Although concurrent toxicities were not
speciﬁed, it is of interest that a recent report indicates
that a 24h duration may be suﬃcient to detect/predict
phospholipidosis accurately by employing a small biomarker
set in toxicogenomic evaluation [17].
Several additional comparisons were made for the
phospholipogenic dataset, particularly regarding physical-
chemical properties and toxicokinetic behavior. Consistent
with the well-described cationic amphiphilic nature of
phospholipogeniccompounds,thephospholipogenicdataset
was comprised mostly of amphiphilic bases and the negative
dataset contained primarily neutrals and acids with only a
few bases. Plasma exposures tended to be lower in animals
dosed with phospholipogenic compounds. For the dog and
mouse, this pharmacokinetic behavior can be explained in
part by the selection of lower phospholipogenic compound

















































































































Figure 6: Percent nonphospholipogenic and phospholipogenic
compoundadministrationsyieldingnon-PLDhistologicalﬁndings,
by organ. For every organ, on average, phospholipogenic admin-
istration resulted in more non-PLD histological ﬁndings than did
negative compound administration. The data represent that pooled
from three species and all study durations.
relative exposures are still lower if dose-normalized (data
not shown). Nominal doses for rat were on average higher
than that of the nonphospholipogenic dataset, but plasma
exposures in the phospholipogenic dataset were considerably
lower. There is an acknowledged general tendency for bases,
and particularly lipophilic bases, to have higher volumes of
distribution[18],althoughithasrecentlybeendemonstrated
that this property alone does not diﬀerentiate phospholi-
pogenics from nonphospholipogenics [19]. Finally, it should
be noted that not only were the average doses and exposures
of the nonphospholipogenic compounds higher, but, as can
be seen in Figure 2, the average duration of their studies
is somewhat longer as well. All of these factors should bias
the number of nonphospholipidosis histological ﬁndings
proﬁle towards the higher dose, higher exposure, longer
study duration group, but, as demonstrated in this study, we
see the opposite.
This thorough and systematic analysis of a large preclini-
cal toxicology dataset containing both conﬁrmed phospho-
lipogenics and nonphospholipogenic compounds indicates
that phospholipogenic administration is likely to be associ-
ated with more and various histological ﬁndings, including
liver toxicities, than do nonphospholipogenic administra-
tions. The data, while compelling, are correlative and cannot
be used to prove causality between phospholipidosis and
toxicities. It should also be noted that speculation on
functional compromise cannot be made and that histologic
ﬁndings identiﬁed in this exercise were not equal in severity.
Findings ranged from relatively benign to severe, and we
did not apply risk assessment analysis where it may beJournal of Toxicology 7
found that compounds could proceed normally through
the drug development process, taking concurrent toxicities,
tissues aﬀected, severity, and safety margins (therapeutic
window) into account. Even with these caveats, it is clear
that phospholipogenic compounds tend to produce more
histological ﬁndings and may require additional monitoring
andriskassessment,therebyincreasingtheoverallburdenon
a drug development project.
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